Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Acrivon Therapeutics, Inc. (ACRV) since 2022 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Acrivon Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1781174.
Total stock buying since 2022: $67,369,250.
Total stock sales since 2022: $3,910,359.
Total stock option exercises since 2022: $174,466.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 2,256,719 | $3,762,864 | 0 | $0 |
| 2024 | 2,353,000 | $20,000,500 | 0 | $0 | 0 | $0 |
| 2023 | 0 | $0 | 12,077 | $147,495 | 52,330 | $174,466 |
| 2022 | 3,789,500 | $47,368,750 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 0 | $0 | 298,886 | $400,507 | 0 | $0 |
| 2025-04 | 0 | $0 | 1,957,833 | $3,362,357 | 0 | $0 |
| 2024-04 | 2,353,000 | $20,000,500 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 12,077 | $147,495 | 18,725 | $44,079 |
| 2023-05 | 0 | $0 | 0 | $0 | 33,605 | $130,387 |
| 2022-11 | 3,789,500 | $47,368,750 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-01 | Edelman Joseph (10% Owner) | Sale | 298,886 | 1.34 | 400,507 |
| 2025-04-30 | Edelman Joseph (10% Owner) | Sale | 437,881 | 1.41 | 617,412 |
| 2025-04-29 | Edelman Joseph (10% Owner) | Sale | 250,000 | 1.41 | 352,500 |
| 2025-04-28 | Edelman Joseph (10% Owner) | Sale | 215,283 | 1.56 | 335,841 |
| 2025-04-25 | Edelman Joseph (10% Owner) | Sale | 1,054,669 | 1.95 | 2,056,604 |
| 2024-04-11 | Edelman Joseph (10% Owner) | Buy | 2,353,000 | 8.50 | 20,000,500 |
| 2023-06-26 | Smolokowski Wiaczeslaw | Sale | 16 | 12.93 | 206 |
| 2023-06-16 | Holm-jorgensen Rasmus (Chief Financial Officer) | Option Ex | 9,500 | 3.63 | 34,485 |
| 2023-06-15 | Smolokowski Wiaczeslaw | Sale | 4,112 | 12.14 | 49,918 |
| 2023-06-14 | Smolokowski Wiaczeslaw | Sale | 893 | 12.13 | 10,832 |
| 2023-06-13 | Smolokowski Wiaczeslaw | Sale | 3,000 | 12.30 | 36,900 |
| 2023-06-12 | Smolokowski Wiaczeslaw | Sale | 2,000 | 12.34 | 24,680 |
| 2023-06-05 | Devroe Eric (Chief Operating Officer) | Option Ex | 9,225 | 1.04 | 9,594 |
| 2023-05-31 | Blume-jensen Peter (President and CEO) | Option Ex | 33,605 | 3.88 | 130,387 |
| 2022-11-17 | Shah Rajeev M. | Buy | 3,389,500 | 12.50 | 42,368,750 |
| 2022-11-17 | Smolokowski Wiaczeslaw | Buy | 400,000 | 12.50 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ACRV listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Acrivon Therapeutics, Inc. (symbol ACRV, CIK number 1781174) see the Securities and Exchange Commission (SEC) website.